MedTrace Logo

Dalteparin in Preventing Blood Clots in Patients With Lung Cancer

NCT00519805 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2200

Last updated 2011-08-08

No results posted yet for this study

Summary

RATIONALE: Anticoagulants, such as dalteparin, may help prevent blood clots from forming in patients with lung cancer. It is not yet known whether dalteparin is effective in preventing blood clots in patients with lung cancer.

PURPOSE: This randomized phase III trial is studying how well dalteparin works in preventing blood clots in patients with lung cancer.

Conditions

Interventions

DRUG

dalteparin

PROCEDURE

quality-of-life assessment

Sponsors & Collaborators

  • Velindre NHS Trust

    lead OTHER_GOV

Principal Investigators

  • Fergus Macbeth, MD · Velindre NHS Trust

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2012-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00519805 on ClinicalTrials.gov